ストックスクリーナーアプリを入手
1.85
0.54%
-0.01
プレマーケット:
1.88
0.03
+1.62%
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns - MSN
MIST Technical Analysis | Trend, Signals & Chart Patterns | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) Proxy Filing Summary - Quartr
Milestone (MIST) Business Update | Q4 2025: Below ExpectationsBlock Trade - Cổng thông tin điện tử tỉnh Tây Ninh
Insider Sell: Joseph Oliveto Sells 36,500 Shares of Milestone Ph - GuruFocus
Milestone (MIST) CEO sells 36,500 shares under Rule 10b5-1 plan - Stock Titan
Why Milestone Pharma stock is taking a dive today - MSN
[144] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
RSI Check: What are the risks of holding Milestone Pharmaceuticals Inc2026 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
Risk Check: Is Milestone Pharmaceuticals Inc a momentum stock2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
MIST: CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway - TradingView
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to Strong-Buy at Raymond James Financial - MarketBeat
Raymond James Financial Initiates Coverage on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Milestone Pharmaceuticals (MIST) Launches RESET-PSVT Study for C - GuruFocus
Milestone Pharmaceuticals plans real-world PSVT registry study By Investing.com - Investing.com Canada
Milestone Pharmaceuticals plans real-world PSVT registry study - Investing.com
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT - The Manila Times
Milestone Pharmaceuticals Announces Registry to Generate Real-World Evidence on Cardamyst Nasal Spray in Patients with Psvt - marketscreener.com
Raymond James initiates Milestone Pharmaceuticals stock coverage with Strong Buy - Investing.com
Raymond James initiates Milestone Pharmaceuticals stock coverage with Strong Buy By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients With PSVT - Bitget
Milestone Pharmaceuticals Expands Market with Cardamyst Nasal Spray Inclusion - StocksToTrade
Gains Report: Can Milestone Pharmaceuticals Inc beat the S P 500IPO Watch & Consistent Income Trade Ideas - baoquankhu1.vn
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Will Freshworks Inc. stock benefit from sector rotationWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Will Milestone (MIST) Stock Rise in 2026 | Price at $1.46, Up 5.43%Community Chart Signals - Cổng thông tin điện tử tỉnh Lào Cai
Buybacks Report: Does Milestone Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Scalable Portfolio Growth Methods - baoquankhu1.vn
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan
Institution Moves: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2026 Earnings Impact & Free Community Consensus Stock Picks - baoquankhu1.vn
Trails Edge Capital Partners, LP Acquires 5,333,333 Shares in Mi - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - Bitget
Milestone Pharmaceuticals (MIST) Secures Formulary Inclusion for Cardamyst - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - The Manila Times
Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Published on: 2026-03-28 09:41:33 - baoquankhu1.vn
Published on: 2026-03-28 10:15:13 - baoquankhu1.vn
Milestone Pharmaceuticals Stock: Trails Edge Discloses 4.3% Stake Amid Q4 Earnings Anticipation - AD HOC NEWS
Trails Edge files amended 4.3% stake disclosure in Milestone Pharmaceuticals (MIST) - Stock Titan
Aug Chart Watch: Is Milestone Pharmaceuticals Incs ROIC above industry averageForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals - Markets Mojo
0.29%
0.00%
大文字化:
|
ボリューム (24 時間):